Skip to main content
    J

    Jasper Therapeutics Inc (JSPR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.77
    -1.91 (-13.96%)

    Market Cap: $15.18M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Jasper Therapeutics Inc (JSPR) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Jasper Therapeutics (JSPR) to earn -$6.90 per share in the fiscal year ending Dec 31, 2026, on revenue of $6.00M. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$21.15.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss.

    Fiscal year ending Dec 31, 2026
    -$6.90
    EPS consensus, revenue $6.00M
    Fiscal year ending Dec 31, 2027
    -$21.15
    EPS consensus
    Next report
    Mar 29, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$6.90-$12.30 to -$1.502$6.00MN/A2
    Dec 31, 2027-$21.15-$39.30 to -$3.002N/AN/A2

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$9.08-$13.52 to -$2.847

    Estimate Revisions

    No EPS estimate for the 2 periods below was revised in the last 30 days.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202600
    Fiscal year ending Dec 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$72.30.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$6.90-$42.30-$72.30-$72.30-$72.30N/A
    Fiscal year ending Dec 31, 2027-$21.15-$58.05-$76.80-$76.80-$76.80N/A

    Frequently Asked Questions About JSPR

    What is the JSPR stock forecast?

    Consensus analyst estimates put Jasper Therapeutics's EPS at -$6.90 for the fiscal year ending Dec 31, 2026, on revenue of $6.00M.

    What EPS do analysts expect from JSPR next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$6.90, with estimates from -$12.30 to -$1.50 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$21.15, with estimates from -$39.30 to -$3.00 from 2 analysts.

    What revenue do analysts expect from Jasper Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $6.00M.

    How many analysts cover JSPR?

    2 analysts estimate EPS for Jasper Therapeutics for the fiscal year ending Dec 31, 2026.